Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2015

View Archived Issues

FDA grants QIDP status to WCK-5222

Vitae Pharmaceuticals begins phase IIa trial of VTP-38543 in atopic dermatitis

First subject dosed in phase I trial of TD-1473

COTI-2 advances into human testing

NORD receives FDA grant to study natural history of rare diseases

Preclinical efficacy of first-in-class TCB antibody EM-801

DMC recommends continuation of phase III trial of AGS-003 in RCC following second interim analysis

Janssen starts first-in-human trial of Aduro's ADU-214 in patients with NSCLC

Anti-HLA-DR antibody IMMU-114 demonstrates activity in first-in-human study

Burixafor/G-CSF promote impressive hematopoietic stem cell mobilization in MM, NHL and HL patients

Interim phase II data for isatuximab in refractory/relapsed multiple myeloma

Ularitide receives FDA fast track designation for acute decompensated heart failure

Agreements signed by Bristol-Myers Squibb, Kyorin, Novartis, Rhizen, AGTC and Synpromics

Ninlaro now available in the U.S.

Synergy seen with CDK9 inhibitors and venetoclax in lymphoma cells

ACE-083 increases muscle volume in phase I study

FDA approves Vistogard to treat overdose or severe toxicities due to 5-FU or capecitabine

GlaxoSmithKline patents ROR-gamma modulators

Mitsubishi Tanabe Pharma discloses MC1 receptor agonists

Novartis reports MALT1 inhibitors

Medshine Discovery introduces anti-HBV compounds

Pfizer discloses Nav1.7 channel blockers

Merck & Co. patents GPR40 agonists

Preclinical and clinical data reported for multiple myeloma candidate ACY-241

Chimeric antigen receptor-modified T cells induce partial remission in first AML patient treated

FDA grants accelerated approval to Alecensa

FDA approves Otiprio for pediatric patients undergoing tympanostomy tube placement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...